HIT Consultant February 26, 2024
What You Should Know:
– Alamar Biosciences, a leader in precision proteomics for early disease detection raises $100M in Series C round, with an additional $28M expected within the next 30 days. This brings their total funding to nearly $250M.
– The Series C funding round was led by led by Sands Capital, with participation from new and existing investors, including both financial and strategic partners. Ian Ratcliffe, Executive Managing Partner at Sands Capital, has joined Alamar’s Board of Directors.
Revolutionizing Early Disease Detection
Alamar’s innovative NULISA technology empowers researchers and clinicians with:
– Unmatched Sensitivity: Utilizing a novel capture and release method, NULISA offers a 10,000-fold improvement in signal-to-noise ratio compared to traditional methods, enabling detection of proteins at...
Today's Sponsors
Today's Sponsor